A personalized mRNA cancer vaccine sponsored by Moderna and Merck has the potential to change the standard of care for melanoma patients—and reshape the landscape of cancer vaccines—if the company’s latest data on the vaccine are validated in a phase III clinical trial.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
